Factors influencing non-approval of new drugs in Europe-Reference-Cited by-同舟云学术

Factors influencing non-approval of new drugs in Europe

Published:2012-11-30 Issue:12 Volume:11 Page:903-904
ISSN:1474-1776
Container-title:Nature Reviews Drug Discovery
language:en
Short-container-title:Nat Rev Drug Discov

Author:

Putzeist Michelle,Mantel-Teeuwisse Aukje K.,Aronsson Bo,Rowland Malcolm,Gispen-de Wied Christine C.,Vamvakas Spiros,Hoes Arno W.,Leufkens Hubert G. M.,Eichler Hans-Georg

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology,General Medicine

Link

http://www.nature.com/articles/nrd3894.pdf

Reference2 articles.

1. Eichler, H. G. et al. New drug approval success rate in Europe in 2009. Nature Rev. Drug Discov. 9, 355–356 (2010).

2. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203–214 (2010).

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report;Clinical Pharmacology & Therapeutics;2024-04-28

2. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies;Clinical and Translational Science;2021-05

3. A review of clinical pharmacology deficiencies of European centralised drug marketing authorisation applications;Regulatory Toxicology and Pharmacology;2020-12

4. Efficacy gap between phase II and subsequent phase III studies in oncology;British Journal of Clinical Pharmacology;2020-02-21

5. Zulassungsverfahren für neue Arzneimittel in Europa;Arzneiverordnungs-Report 2019;2019